Patents by Inventor Chuangchuang Huang

Chuangchuang Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR
    Publication number: 20230271968
    Abstract: Disclosed is a compound of a general formula (I), which may be used for the treatment of ATR kinase-mediated diseases, for example, proliferative diseases such as cancer. Further disclosed are a preparation method for the compound of the general formula (I), a pharmaceutical composition, and use of the pharmaceutical composition for the treatment of ATR kinase-mediated diseases.
    Type: Application
    Filed: July 13, 2021
    Publication date: August 31, 2023
    Inventors: Cheung Ling Cheng, Yanping Zhao, Hongjun Wang, Bin Liu, Weiting Zhong, Huifen Xu, Chuangchuang Huang, Jing Li, Weina Liu
  • 2,4,6-TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS
    Publication number: 20230212160
    Abstract: Provided are compounds represented by general formula (I), which can be used for treating ATR kinase-mediated diseases, such as proliferative diseases, such as cancer. Further provided are a pharmaceutical composition of the compound represented by general formula (I), a use thereof in treating ATR kinase-mediated diseases, and a preparation thereof.
    Type: Application
    Filed: May 20, 2021
    Publication date: July 6, 2023
    Inventors: Yanping Zhao, Bin Liu, Yuanyuan Jiang, Weiting Zhong, Huifen Xu, Hongjun Wang, Li Mao, Jingtao Li, Honglei Zhang, Chuangchuang Huang, Jing .. Li, Jing Zhao, Weina Liu, Nana Tian, Liying Zhou, Yanan Liu
  • 2, 4, 6-TRI-SUBSTITUTED PYRIMIDINE COMPOUND AS ATR KINASE INHIBITOR
    Publication number: 20220378799
    Abstract: Compounds of general formula (A) can be used for treating ATR kinase-mediated diseases, for example, hyperplastic diseases such as cancers. Also provided are a pharmaceutical composition of the compounds of general formula (A), a use of the pharmaceutical composition for treating the ATR kinase-mediated diseases and a preparation method for the pharmaceutical composition.
    Type: Application
    Filed: June 5, 2020
    Publication date: December 1, 2022
    Inventors: Yanping Zhao, Hongjun Wang, Bin Liu, Yuanyuan Jiang, Weiting Zhong, Huifen Xu, Honglei Zhang, Chuangchuang Huang, Nana Tian, Jing Zhao, Jing Li, Weina Liu, Liying Zhou, Yanan Liu